Breaking News Instant updates and real-time market news.

DCPH

Deciphera

$35.88

15.97 (80.21%)

07:35
08/14/19
08/14
07:35
08/14/19
07:35

Deciphera price target raised to $29 from $20 at SVB Leerink

SVB Leerink analyst Andrew Berens raised his price target for Deciphera to $29 from $20 following positive top-line data from the company's Phase 3 INVICTUS trial that exceeded his expectations, in addition to favorable updates to the Phase 1 ripretinib data. The analyst reiterates an Underperform rating on the shares.

  • 15

    Aug

DCPH Deciphera
$35.88

15.97 (80.21%)

08/13/19
08/13/19
NO CHANGE
Target $68

Buy
Deciphera INVICTUS results best-case scenario, price target raised at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt raised his price target for Deciphera (DCPH) to $66 from $44 after the company announced top-line results from the Phase 3 INVICTUS study of ripretinib in 4L+ GIST, which he believes "significantly exceeded" investors' expectations and validated his bullish thesis and analyses heading into the binary event. The analyst notes that results included a 6.3 months mPFS readout in a setting with no approved therapies and also compare favorably to competitor data from Blueprint Medicines (BPMC) in similar patients. Together with updated Phase 1 ripretinib data across 2L and 3L GISTs, Schmidt thinks these results read-through positively also for the drug's potential in earlier stage GIST patients. Deciphera's Phase 3 INTRIGUE trial in 2L GIST will complete enrolling in the second quarter of 2020, he adds. The analyst has a Buy rating on Deciphera's shares.
08/13/19
DBAB
08/13/19
NO CHANGE
DBAB
Buy
Deciphera price target raised to $66 after cancer data at Deutsche Bank
Deciphera Pharmaceuticals in late morning trading is up 97%, or $19.32, to $39.27.
08/14/19
ADAM
08/14/19
NO CHANGE
Target $65
ADAM
Buy
Deciphera price target raised to $65 from $50 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Deciphera to $65 from $50 following positive topline Phase3 ripretinib 4L GIST data. The analyst said the results significantly met its primary endpoint and showed notable benefit in RR and OS. He views the data as highly competitive and views its proprietary kinase switch control-based pipeline as attractive. Lee reiterated her Buy rating on Deciphera shares.
08/14/19
CANT
08/14/19
NO CHANGE
Target $55
CANT
Overweight
Deciphera price target raised to $55 from $43 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Deciphera Pharmaceuticals to $55 from $43 and reiterates an Overweight rating on the shares. The analyst has increased conviction of the ripretinib programs following yesterday's topline data presented for the Phase 3 trial of ripretinib in gastrointestinal stromal tumors and "incrementally positive" update from the Phase 1 study across all lines of GIST treatment. Duncan also sees a larger total addressable market beyond his current model as a result of the recent licensing of ripretinib for development and commercialization in China to Zai Lab.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.